Background: The resistant to current therapy against tuberculosis is tremendously
increasing, novel potential anti-tubercular compounds should be developed at
the urge. The presently reported analogues act by binding to the kat-G gene present in
Mycobacterium tuberculosis which converts them into active form, thereby inhibiting
inhA mediated mycolic acid synthesis.
Objective: To establish structure activity relationship, identify key features and find out
the binding orientation of the compounds to the katG gene present in Mycobacterium
tuberculosis for the treatment of tuberculosis.
Methods: In the present work, 2D Quantitative Structure Activity Relationships, 3D
Quantitative Structure Activity Relationships, pharmacophore mapping and docking studies
of isoniazid derivatives have been carried out with V-life Molecular Design Suite 4.2,
Schrodinger and GOLD (Genetic Optimization for Ligand Docking) program. The model
was developed by PLS (Partial Least Square) and kNN (k-nearest neighbour) as variable
Results: The best 2D Quantitative Structure Activity Relationships model was developed
with r2 = 0.9688 and q2 = 0.8082 and correlated the effect of descriptors on the biological
activity. The best 3D Quantitative Structure Activity Relationships model showed a crossvalidated
correlation coefficient (q2) of 0.7332 and a predicted r2 for the external test
(pred_r2) of 0.9032. The pharmacophore analysis represented that the features such as
hydrogen bond acceptor, hydrogen bond donor and aromatic ring were essential for the
anti-tubercular activity. When docked, the isoniazid derivatives showed good binding
affinity to the receptor even in resistant cases (mutant type) and showed favourable
fitness scores in-silico as compared to isoniazid.
Conclusion: The whole studies served as a basis for the development of better potential
therapeutic compounds for anti-tubercular activity.